2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1603

Safety of Biologic and Non-Biologic Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Veterans with Rheumatoid Arthritis and Chronic Hepatitis C Infection
Abstract Number: 1604

Cardiovascular Disease in a Large Incident Cohort of Early Inflammatory Arthritis
Abstract Number: 1605

Enhanced Oxidant Signaling in Inflammatory Macrophages in Rheumatoid Arthritis (RA) and in Coronary Artery Disease (CAD)
Abstract Number: 1606

Telomere Damage in Rheumatoid Arthritis
Abstract Number: 1607

Rheumatoid Factor Is Associated with the Distribution of Hand Joint Destruction in a Dose-Dependent Manner
Abstract Number: 1608

Protective Role of the Vitamin D Receptor Apai (rs7975232) Polymorphism Against Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis from Northern Spain
Abstract Number: 1609

Lack of Association Between ZHX2, Lepr, Gckr and ASCL1 and Carotid Intima-Media Thickness, Carotid Plaques and Cardiovascular Disease in Patients with Rheumatoid Arthritis
Abstract Number: 1610

DNA Methylation Changes Observed in Rheumatoid Arthritis Joint Tissue Are Detectable in CD4+ Naive T Cells from Peripheral Blood
Abstract Number: 1611

Gene Expression Profiling Reflects Increased Expression of Coronary Artery Disease Associated Genes in a Case-Control Matched Study of Patient with Rheumatoid Arthritis
Abstract Number: 1612

Association of Single Nucleotide Polymorphisms of PADI4 and HLA-DRB1 Alleles with Susceptibility to Rheumatoid Arthritis-Related Lung Diseases
Abstract Number: 1613

Expression of the Genes Facilitating Methotrexate Action within Rheumatoid Subcutaneous Nodules
Abstract Number: 1614

The Impact of High Risk Susceptible Gene LILRA3 on Joint Inflammation in Rheumatoid Arthritis
Abstract Number: 1615

Lack of Replication of the Association Between Anti-Citrullinated Fibrinogen and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Abstract Number: 1616

Identification of Genes Regulating TRAIL-Induced Apoptosis in Rheumatoid Arthritis Fibroblasts-like Synoviocytes (RA FLS)
Abstract Number: 1617

Evidence for Citrullinated Inhibitor of DNA Binding 1 (Id1) As a Novel Autoantigen Candidate in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].